Collaborations between academic, industrial, and nonprofit companies can provide sufficient impetus to propel projects that have little economic return; such projects are prevalent in tropical disease drug discovery. In these collaborations, each partner contributes a unique set of skills and technical expertise which is advantageous to the project as a whole. Highly product-focused processes and specialized expertise sets dominate industry groups. When coupled with the strategic guidance from public–private partnerships and the academic tendency to work on high-risk projects with low financial rewards, a powerful combination results. There are numerous examples throughout the literature about these collaborative efforts to combat a variety of tropical diseases (including leishmaniasis, Chagas disease, African sleeping sickness, and malaria), from all stages of the drug discovery process to the advancement of new drugs into the clinic. However, there is still uncertainty from many academic institutions as to how to establish and engage in these research consortiums. This Viewpoint highlights opportunities, benefits, and suggestions for productive collaborations in this disease space.

中文翻译：

---

工业界，学术界和非营利组织之间的合作在热带病药物发现中的重要性

学术，工业和非营利性公司之间的合作可以提供足够的动力来推动经济收益很少的项目；这样的项目在热带疾病药物的发现中很普遍。在这些合作中，每个合作伙伴都贡献了一套独特的技能和技术专长，这对整个项目都是有利的。高度以产品为中心的流程和专业知识集主导着整个行业群体。再加上公私合作伙伴关系的战略指导，以及学术上倾向于开展低风险，低回报的高风险项目的努力，就会形成强有力的结合。在整个文献中，有许多关于抗击各种热带疾病（包括利什曼病，南美锥虫病，非洲昏睡病和疟疾）的合作努力的例子，从药物发现过程的所有阶段到新药进入临床的过程。但是，许多学术机构对于如何建立和参与这些研究财团仍存在不确定性。该观点重点介绍了在该疾病领域进行生产性合作的机会，收益和建议。